Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 24

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 24
---
 the board. Dr. Bonita has attended every meeting of the board, compensation committee and science & technology committee over the past three years. He is consistently prepared for, and actively participates in, each meeting he attends with the board and Repare management. His service on the other public company boards also meets the requirements of our corporate governance guidelines, which allow service on no more than a total of five public company boards. In the case of Ms. Schafer, she has served as a member of our board since March 2019. Currently, Ms. Schafer sits on four public company audit committees (including our audit committee). The board of directors believes that Ms. Schafer’s experience, expertise, independence, and institutional knowledge, especially with respect to our auditing processes and our financial history, planning, and strategy, make her a valuable member of our audit committee. As a member of our audit committee, Ms. Schafer provides thoughtful and detailed feedback on our corporate accounting and financial reporting processes and also provides critical insights on our financial strategy. Ms. Schafer also plays a crucial role on our board as chair of the nominating and corporate governance committee, and has demonstrated her commitment to our board by attending all but one meeting of the board and the committees on which she has served as a member. Accordingly, the board believes that Ms. Schafer’s service on three other public companies’ audit committee does not, and will not, negatively impact her service on our audit committee. Her service on the other public company audit committees also meets the requirements of our corporate governance guidelines, which allow service on no more than a total of four public company audit committees. Board Refreshment A thorough and in-depthreview is conducted for the directors whose term will expire at the next annual meeting of shareholders. The review assesses each director based on such director’s board and committee experience to date and the skills and experiences deemed appropriate to meet the current and future needs of our board of directors and Repare. The review consists of a two-partprocess to determine if each director should seek another three-year term.

| • |     | Members of the nominating and corporate governance committee conduct one-on-one reviews with each director to ensure maximum frankness, confidentiality and respect for the individual. These meetings are designed to gain the directors’ perspective on their contributions to the board of directors and whether they believe continuing for another term is appropriate and advisable. |

15

| • |     | The nominating and corporate governance committee then meets in executive session, along with the chair of the